josh hardman

At-Home Ketamine “Completely Irresponsible”, Says UK Expert

“In the psychedelic world, we are very aware that context is important,” Professor Celia Morgan said, referring to set and setting, as well as the social matrix surrounding the drug user.

psychedelicalpha.com/news/therapy...

Therapy or Threat? UK Expert Warns of Rising Ketamine Addiction as Phase III Alcoholism Trial Launches - Psychedelic Alpha Psychedelic Alpha’s Charles Bliss speaks with Professor Celia Morgan, a leading ketamine researcher, about the promise of ketamine-assisted therapy for alcohol use disorder…

Therapy or Threat? UK Expert Warns of Rising Ketamine Addiction as Phase III Alcoholism Trial Launches

Charles Bliss speaks with Professor Celia Morgan about ketamine's promise and pitfalls.

psychedelicalpha.com/news/therapy...

Last Week in Psychedelics.

Bookmark the live Feed: psychedelicalpha.com/live

Pα+ Psychedelic Bulletin #205: AbbVie Eyes Gilgamesh; Psychedelics Use Increases in U.S.; FDA Moves to Ban Kraton Compound 7-OH; What Is Sinema Selling? - Psychedelic Alpha AbbVie Eyes Billion-Dollar Gilgamesh Acquisition • What Is Kyrsten Sinema Selling? • Compass ‘Encouraged’ by Germany’s Psilocybin Compassionate Use Program • Psychedelics Industry’s Input on EMA’s Dra...

Pα+ Psychedelic Bulletin #205:

- AbbVie Eyes Gilgamesh

- Psychedelics Use Increases in U.S.

- FDA Moves to Ban Kraton Compound 7-OH

- What Is Sinema Selling?

- and much, much more (5,000+ words!)

psychedelicalpha.com/news/p%ce%b1...

Germany joins Switzerland in allowing certain European patients to access psilocybin when they have exhausted other options.

The imprimatur of Swiss engineering & German efficiency and process-focus could add to psychedelic medicine’s legitimacy.

More: psychedelicalpha.com/news/germany...

Germany Establishes EU’s First Psilocybin Compassionate Access Program - Psychedelic Alpha Germany has become the first EU country to allow legal access to psilocybin under a compassionate use program for treatment-resistant depression. Unlike other countries’ pre-approval pathways, Germany...

BREAKING: German regulators have green-lit the EU's first psilocybin compassionate access program.

Unlike other countries’ pre-approval pathways, Germany’s does not require case-by-case regulatory approval and may see insurers cover costs.

Details: psychedelicalpha.com/news/germany...

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Circuitry, Consciousness, and Clinical Horizons (Part 2) - Psychedelic Alpha In this second Dispatch from the inaugural Neurobiology of Psychedelics Gordon Research Conference, Dr. Alaina Jaster recaps Days 2 through 4, highlighting cutting-edge research on neuroplasticity…

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Circuitry, Consciousness, and Clinical Horizons (Part 2)

Reporting by @jasteralaina.bsky.social.

The entire Dispatch is now free to read.

psychedelicalpha.com/news/dispatc...

Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice; Makary’s Priority Voucher Pilot Launches, Mentions Innovative PTSD Treatments; HALT Fentanyl Act Could Streamline Schedule I Re... FDA Keeps GH Research’s 5-MeO-DMT on Ice as atai and Beckley Surge Ahead • Makary’s Priority Voucher Program Launches, Cites Novel PTSD Treatment as Example • HALT Fentanyl Act Signed by Trump, Could ...

Pα+ Psychedelic Bulletin #204

📍 FDA Keeps GH Research’s 5-MeO-DMT on Ice

📍 Makary’s Priority Voucher Pilot Launches, Mentions Innovative PTSD Treatments

📍 HALT Fentanyl Act Could Streamline Schedule I Research

📍 and more...

psychedelicalpha.com/news/p%ce%b1...

Q3 2025: Psychedelic Investor Survey

If you have invested in, or are considering investing in, a psychedelics-related company, please complete our latest Psychedelic Investor Survey.

docs.google.com/forms/d/1T_r...

Pα+ Psychedelic Bulletin #203: Norway Considers Funding Off-Label Ketamine for TRD; Longevity Crowd Hypes Psilocybin Study; Will State-Legal Psychedelics Eat Psychedelic Pharma’s Lunch? - Psychedelic ... Norway’s Health System Considers Funding Off-Label Ketamine for Treatment-Resistant Depression • Spravato’s Monotherapy Success Puts Pressure on Psychedelics Developers • Longevity Crowd Hypes Psilocy...

Pα+ Psychedelic Bulletin #203:

🔑 Above the Paywall: Norway’s Health System Considers Funding Off-Label Ketamine for Treatment-Resistant Depression

🐁 Longevity Crowd Hypes Psilocybin Study But Researchers Urge Caution

and more...

psychedelicalpha.com/news/p%ce%b1...

Psychedelic Funding Update: Q2 2025 - Psychedelic Alpha Q1 2025 saw around $152M flow into psychedelics companies, with Lykos Therapeutics’ $50M Series B round representing one of the first major private financings in quite some time. Explore key trends…

Q2 2025 Psychedelic Funding Update

Just over $150M flowed into psychedelic companies in Q2, all of which were drug developers. That's down around 60% from Q1.

Explore the data and analysis:
psychedelicalpha.com/news/psyched...

Thanks, Bryan!

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook - Psychedelic Alpha In a candid conversation with Psychedelic Alpha’s Josh Hardman, former U.S. Senator Kyrsten Sinema shares her case for ibogaine, sidesteps what she describes as ‘drama’, and lays out a strategy for…

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

I sat down with former U.S. Senator Kyrsten Sinema to discuss her advocacy for ibogaine.

psychedelicalpha.com/news/from-se...

Oregon Psilocybin Services Tracker: Q1 2025 - Psychedelic Alpha As the first cut of data from Oregon’s psilocybin program becomes available, we take a deep dive into emerging trends through various data visualisations and analysis. This marks the first instalment…

NEW: Oregon Psilocybin Services Tracker

As the first cut of data from Oregon’s psilocybin program becomes available, we publish our first Oregon Psilocybin Services Tracker, which takes a deep dive into emerging trends through data visualisations & analysis.

psychedelicalpha.com/news/oregon-...

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Read our interview with Chris Timmermann:
psychedelicalpha.com/news/reconst...

Lorde Gets Over Stage Fright with MDMA-Assisted Therapy

Speaking with Stephen Colbert on The Late Show, Kiwi singer Lorde said that MDMA-assisted therapy “truly changed the game on my stage fright.”

Mike Burke is Lykos Therapeutics' new CEO.

Former FDA reviewer and (for a brief stint) MindMed VP R&D Javier Muniz joins as CMO.

Former CEO Amy Emerson joins Board.

Pα+ Psychedelic Bulletin #202: Psychedelics Access ‘Within 12 Months’, RFK Jr. Says; Psychedelics in Washington; Lykos’ New CEO, CMO; New Zealand’s First Psilocybin Prescriber; Judge Recommends Schedu... RFK Jr. Envisages Psychedelics Access ‘Within 12 Months’ • Psychedelics in Washington: FDA, VA, and New Political Signals • Lykos Therapeutics’ New CEO and CMO, Amy Emerson Joins Board • New Zealand A...

Pα+ Psychedelic Bulletin #202:

- Psychedelics Access ‘Within 12 Months’, RFK Jr. Says; Psychedelics in Washington

- Lykos’ New CEO, CMO

- New Zealand’s First Psilocybin Prescriber

- Judge Recommends Schedule I Placement for DOI and DOC

- and more...

psychedelicalpha.com/news/p%ce%b1...

Compass Pathways’ Psilocybin Clears First Phase 3 Hurdle

“Rest assured, we’ve got something pretty special here”, Chief Commercial Officer Englebert told Psychedelic Alpha.

psychedelicalpha.com/news/compass...

Australia’s Largest Private Health Insurer Commits $10M to Fund MDMA Therapy for PTSD in First-of-its-Kind Program - Psychedelic Alpha Australia’s largest private health insurer, Medibank, has launched a first-of-its-kind funding program for MDMA-assisted therapy for PTSD as part of its ‘innovative psychotherapy program’.

Australia’s largest health insurance company, Medibank, has carved out AUD $10M (USD $6.5M) to fund a psychedelic therapy pilot program for its eligible members, who won’t pay a penny in out-of-pocket costs.

psychedelicalpha.com/news/austral...

May 2025 Psychedelic Patent Update: Gilgamesh Broadens Moat Around Lead Candidate Following Positive Phase 2a Readout; Lykos Publishes Further Continuation Applications; Reconnect Joins Crowded 5-MeO-... Explore or interactive database of psychedelic patent activity in May 2025 via our Pα+ interface. We also cover a handful of related headlines: from Gilgamesh Pharmaceuticals’ IP around its lead…

May 2025 Psychedelic Patent Update:

- Gilgamesh Broadens Moat Around Lead Candidate Following Positive Phase 2a Readout

- Lykos Publishes Further Continuation Applications

- Reconnect Joins Crowded 5-MeO-DMT Patent Landscape

psychedelicalpha.com/news/may-202...

Pα+ Psychedelic Bulletin #200: Can Czechia Deliver on Psilocybin Access? A Closer Look at ‘atai Beckley’; Q1’25 Psychedelic Lobbying Update; Catching Up with the Class of Bulletin #100 - Psychedelic A... The Class of Bulletin #100: Where Are They Now? • Can Czechia Deliver on Psilocybin Access and Provide a Model for the Continent? • A Closer Look at atai’s Potential Acquisition of Beckley Psytech • Q...

Psychedelic Bulletin #200:

📌Can Czechia Deliver on Psilocybin Access?

📌A Closer Look at ‘atai Beckley’

📌Q1’25 Psychedelic Lobbying Update

📌Catching Up with the Class of Bulletin #100

📌 and much more.

Read for free: psychedelicalpha.com/news/p%ce%b1...

The Backyard Psychedelic Renaissance: How Bottom-Up Change Is Delivering Psychedelic Access - Psychedelic Alpha Policy analyst Kody Zalewski calls for a greater focus on local reforms as a key driving force behind future reforms over larger geographies, and foregrounds some of the voices who are joining him in…

The Backyard Psychedelic Renaissance: How Bottom-Up Change Is Delivering Psychedelic Access

A Guest Article by policy analyst Kody Zalewski.

psychedelicalpha.com/news/the-bac...

📫 Each Sunday, we at Psychedelic Alpha send our Psychedelic News Feed to fifteen thousand psychedelics insiders.

Bookmark the live News Feed and subscribe for free to get the Sunday roundup: psychedelicalpha.com/live

🔗 Links to all the stories mentioned above can be found there, too.

Breaking: atai Moves to Acquire Beckley, If Phase 2b 5-MeO-DMT Data Delivers - Psychedelic Alpha Psychedelic drug developers atai Life Sciences and Beckley Psytech are set to merge in a transaction that would value Beckley at around $370M. The combined entity, which would be named atai Beckley…

BREAKING: atai Moves to Acquire Beckley, If Phase 2b 5-MeO-DMT Data Delivers

atai has struck an option-like deal with Beckley Psytech: it will acquire the latter in an all-share transaction should its Phase 2b readout meet prespecified criteria.

psychedelicalpha.com/news/breakin...

BREAKING: Czech Republic Set to Allow Medical Use of Psilocybin

If approved by the Senate next month, it will become the third country in the world to allow access to a psychedelic ahead of conventional marketing approval.

After Controversy, the Psilocybin & Religious Leaders Study Is Finally Published

Johns Hopkins and NYU have released their research on the effects of psilocybin on religious leaders via a journal article in Psychedelic Medicine.

The study: www.liebertpub.com/doi/10.1089/...

Pα+ Psychedelic Bulletin #199: Lykos Takeover Nears Completion; Fewer than 100 Patients Received Psychedelics in Australia During First 18 Months of Access; Ibogaine Bill Clears Texas Legislature Amid... New CEO Tapped as Gracias and Hohn Close In on Lykos Takeover • Data Reveals Fewer than 100 Patients Received Psychedelics in Australia During First 18 Months of Access • Ibogaine Bill Clears Texas Le...

Psychedelic Bulletin 199:

📌 New CEO Tapped as Gracias & Hohn Close In on Lykos Therapeutics Takeover

📌 Data Reveals <100 Patients Received Psychedelics in Australia During First 18 Months

📌 Ibogaine Bill Clears Texas Legislature Amid THC Crackdown

psychedelicalpha.com/news/p%ce%b1...

Can a State Fast-Track a Psychedelic Breakthrough? Inside Texas’ Plan to Fund Ibogaine Trials - Psychedelic Alpha Texas is on the verge of launching the largest publicly funded psychedelic research initiative in U.S. history: a $50 million public-private partnership to support FDA-approvable ibogaine trials.

Texas is on the verge of launching the largest publicly funded psychedelic research initiative in U.S. history: a $50 million public-private partnership to support FDA-approvable ibogaine trials.

Here, I look at the questions that remain...

psychedelicalpha.com/news/can-a-s...

Gilgamesh’s Next-Gen Psychedelic GM-2505 Prints Impressive Results in Phase 2a Major Depressive Disorder Study - Psychedelic Alpha As Gilgamesh Pharmaceuticals is set to share positive results from its Phase 2a study of GM-2505 (aka bretisilocin, a serotonergic psychedelic) in major depressive disorder later today at ASCP…

New: We take a closer look at Gilgamesh's positive Phase 2a results of GM-2505 (aka bretisilocin, a serotonergic psychedelic) in major depressive disorder (MDD) & speak to company execs

The results should provide a welcome catalyst for the field.

psychedelicalpha.com/news/gilgame...